Jazz Pharmaceuticals Stock (NASDAQ: JAZZ)

Jazz Pharmaceuticals Stock (NASDAQ:JAZZ), Trade Ideas

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

ezgif-2-a9d7c7d0e4

Cannabis

News

Events

AAWH

JAZZ

TLRY

How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health &amp; Innovation

Charlotte Figi

Exclusives

Interview

If there&#39;s love that could move the Earth, it&#39;s that of a parent towards a child. And, as the Chinese proverb says, ‘To understand your parent&#39;s love, you must raise children yourself.&#39; Today&#39;s story is about a mother who once moved mountains for her daughter and continues to do the same for other struggling parents with children who are ill.

Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter &amp; Still Advocates For Millions Of CBD Users

Photo- EmilyPaxhia_PoseidonAssetManagement PedroLastra_Unsplash-1

The Queen Of Marijuana Investing Used Psychology To Launch Her Successful Cannabis Investment Fund

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target is $196.6, accompanied by a high estimate of $235.00 and a low estimate of $131.00. A decline of 0.87% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1712757679_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$188.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Jazz Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Jazz Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Jazz Pharmaceuticals Better</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Understanding the Numbers: Jazz Pharmaceuticals's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 4.1%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.83% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 1.55. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views

Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and maintains $180 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target

CORRECTION: Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application For Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Following President Biden&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/03/37552483/biden-calls-for-cannabis-reform-in-state-of-the-union-a-historic-first-no-one-should-be-jailed-f">brief mention</a> of cannabis reform in the State of the Union speech last month and VP Kamala Harris&#8216;s recent plea to the DEA to accelerate the process of rescheduling cannabis <a href="https://www.benzinga.com/markets/cannabis/24/03/37760731/vp-kamala-harris-urges-dea-to-reschedule-cannabis-as-quickly-as-possible-calls-prohibition-absur" target="_blank" rel="noreferrer noopener">under the Controlled Substances Act</a>, there has been much speculation about what&#8217;s next and when.
Meanwhile, cannabis companies are figuring out ways to stay afloat and attract investors. Suggestions and ideas on how to do that are on the docket at the upcoming <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> this April 16-17 where Morgan Paxhia of Poseidon Investment Management and John Darwin of Luminous Capital will share their vast industry experience. 
To say that the last couple of years have been challenging for cannabis companies would be an understatement. High taxes, regulatory challenges, no banking options and a booming illicit market are some of the stumbling blocks on the road. Despite this, some companies grew. According to <a href="https://www.benzinga.com/markets/cannabis/23/03/31583301/environment-in-the-cannabis-industry-is-so-bad-its-good-says-jason-wild-of-terrascend" target="_blank" rel="noreferrer noopener">experts,</a> successful companies are the ones that keep their focus on their balance sheets and make their businesses sustainable.
<h2 class="wp-block-heading">Financial Health And Innovation </h2>
Financial health is one of the factors investors have been and will continue to look for in 2024. Paxhia and Darwin will share ideas. 
In 2014, Poseidon made a bold move of investing in plant-touching companies, which turned out to be a smart move, as the company now has three funds that are closed to new investors. Commenting on the latest earnings season, Paxhia <a href="https://www.linkedin.com/in/morganpaxhia/recent-activity/all/" target="_blank" rel="noreferrer noopener">said</a> that while some companies performed well, others continue to struggle with too much leverage and past capital allocation decisions. "We expect the gap in performance to continue, especially in the absence of any Federal progress," adding that he&#8217;s optimistic that rescheduling cannabis will <a href="https://www.benzinga.com/markets/cannabis/24/01/36578319/this-one-factor-could-reignite-growth-in-us-cannabis-industry-says-seasoned-investor" target="_blank" rel="noreferrer noopener">reignite growth in U.S. cannabis</a>. 
Poseidon was the first fund to recognize the potential of some of the largest companies in the industry. For example, it invested in cannabis operator Aphria, which was later bought by Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>).  Then there&#8217;s CBD drug company GW Pharmaceuticals, which developed and produced Epidiolex, the only FDA-approved prescription CBD treatment for severe forms of epilepsy. GW Pharma was <a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio" target="_blank" rel="noreferrer noopener">acquired by</a> Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>). Other big marijuana players include Headset, FlowHub and Ascend Wellness (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTCQX">AAWH</a>). 
Luminous Capital
Darwin identifies investments, guides debt and equity investment strategies and manages portfolio companies. He brings extensive experience from his roles in the cannabis industry and private equity. Darwin co-founded One Cannabis, a US-based cannabis dispensary franchisor and grew it from inception to vertically integrated operator with large-scale cultivation and branding strategies across multiple states. He guided the company to success amid the challenges in the industry. 
He recently shared his enthusiasm about the struggling New York marijuana landscape, which will be another hot topic at the event. 
In addition to financial health, is it innovation that investors are looking for in the cannabis space in 2024? 
Learn from Darwin, who will share his experience in strategic guidance, comprehensive risk understanding and value-added investing. 
<h3 class="wp-block-heading">Learn from experts Morgan Paxhia and John Darwin</h3>
The <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">The Diplomat Beach Resort</a> will be a chance for entrepreneurs, both large and small, to network, learn, and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Get your tickets now on&nbsp;</a><a href="http://bzcannabis.com/" target="_blank" rel="noreferrer noopener">bzcannabis.com</a><a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">&nbsp;– Prices will increase very soon!</a>
Photo: AI-Generated Image.&nbsp;

How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation

Truist Securities analyst Joon Lee reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

Truist Securities Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

Throughout the last three months, 12 analysts have evaluated Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $196.58, a high estimate of $235.00, and a low estimate of $131.00. This current average has decreased by 2.63% from the previous average price target of $201.88. 
<img src="https://www.benzinga.com/files/images/story/2024/1710943241_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$188.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Jazz Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Jazz Pharmaceuticals Better</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.1% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 2.61%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.83%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.55, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and raises the price target from $171 to $188.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $188

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and raises the price target from $171 to $188.

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $188

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $220 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $220 Price Target

Stifel analyst Annabel Samimy maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $225 to $230.

Stifel Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $230

HC Wainwright &amp; Co. has decided to maintain its Buy rating of Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) and lower its price target from $204.00 to $200.00.
Shares of Jazz Pharmaceuticals are trading up 0.2% over the last 24 hours, at $118.00 per share.
A move to $200.00 would account for a 69.49% increase from the current share price.
<h3>About Jazz Pharmaceuticals</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know

HC Wainwright &amp; Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and lowers the price target from $204 to $200.

HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $200

If there&#39;s love that could move the Earth, it&#39;s that of a parent towards a child. And, as the Chinese proverb says, &lsquo;To understand your parent&#39;s love, you must raise children yourself.&#39; Today&#39;s story is about a mother who once moved mountains for her daughter and continues to do the same for other struggling parents with children who are ill.
Paige Figi is an executive director of Coalition for Access Now, a non-profit that educates the public and lawmakers about the health benefits of Cannabidiol, or CBD. Her journey into this world was born out of her journey of motherhood.
In 2020 her four-year-old daughter, Charlotte, born with a severe form of pediatric epilepsy called Dravet Syndrom, had failed all standard pharmaceutical options. She &quot;was seizing 50 times a day, on life support, her prognosis looking worse by the day,&quot; Figi told Benzinga. &quot;I turned to scientists studying Cannabidiol as a potential therapy for epilepsy. I searched for experts in Colorado to help create an extract under strict breeding, farming, extracting, and testing criteria&hellip;what we now call CBD.&quot;
It turned out that this non-intoxicating hemp extract, high in CBD and low in THC was extremely effective in treating Charlotte&#39;s epilepsy, allowing her to live a non-medical, pharmaceutical-free life.
Charlotte became famous worldwide after appearing in the <a href="https://www.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/index.html">2013 CNN documentary</a> hosted by Dr. Sanjay Gupta called &quot;Weed.&quot;
This little girl inspired the creation of <a href="https://www.benzinga.com/topic/epidiolex">Epidiolex</a>, the groundbreaking FDA-approved cannabinoid seizure medication. The first <a href="https://www.benzinga.com/markets/cryptocurrency/18/06/11929452/gw-pharmas-epidiolex-becomes-first-cannabis-based-fda-approved" rel="noreferrer noopener" target="_blank">FDA-authorized CBD medicine</a> Jazz Pharmaceuticals&#39; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures" rel="noreferrer noopener" target="_blank">for treating seizures related to tuberous sclerosis complex</a>.
Charlotte Figi was the catalyst, or as Gupta said she was &quot;more than an individual, she was an entire movement.&quot;
Now, her story continues to help people around the world, thanks to her mother.
&quot;Epilepsy parents in similar predicaments across the world heard our success story, wanted access and were faced with the predicament of lack of legal access,&quot; Figi said. And while CBD and hemp were federally illegal at the time, in Colorado they were legally available under state medical marijuana laws.
At the time, parents from outside the often made the difficult decision to relocate to Colorado and become residents.
&quot;I started the Coalition for Access Now to fix antiquated state and federal laws to allow for CBD access and help get those families back home. The nonprofit was created out of the necessity to represent the American CBD consumer, educate the public, and work with lawmakers.&quot;
<img alt="" class="wp-image-248809" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/12130211/u_7qb33S_400x400-1.jpg" style="height:400px; width:400px" />
Courtesy photo 
<h2 class="wp-block-heading">45 Million Users In A &lsquo;Wild West&rsquo; CBD Market</h2>
When Donald Trump signed the Agriculture Improvement Act of 2018, which effectively legalized hemp and hemp-derived products on the federal level, things became easier for those in need of this God-given natural medicine. Unfortunately, though, not everything around hemp and CBD was regulated under the Farm Act 2018. Products derived from hemp were not regulated as food or supplements.
This has created &quot;the &lsquo;Wild West&#39; of a blooming and unregulated CBD market,&quot; Figi explains. &quot;Many products are untested, inaccurately labeled, contain heavy metals and other toxins due to irresponsible farming practices of a soil-cleansing plant, and it is the great unknown of what amount of milligrams CBD may be in a product.&quot;
She said that as many as 45 million Americans take CBD products daily, &quot;and to represent them responsibly means we place consumer safety at the forefront. Childhood epilepsy is now the smallest percentage of CBD consumers and we speak for seniors, athletes, first responders, and our military veteran community. All of these groups and more see benefits from this alternative therapy and deserve to have products that are safe and accessible. &quot;
<h2 class="wp-block-heading">Time Is The Enemy&nbsp;</h2>
When she started the Coalition For Access Now, Figi recalls time as the enemy, &quot;because of the nature and severity of untreatable, life-limiting, pediatric epilepsy.&quot;&nbsp;
Fortunately, though, Congress got involved and crafted the first bills that carried Charlotte&#39;s name. While the first part of the effort &ndash; de-scheduling hemp and CBD was undertaken. The second part, which involves allowing the FDA to regulate it as a dietary supplement, is still in the works.
&quot;The second part and last mile of a 14-year effort is what I am working on still to this day,&rdquo; Figi says. &ldquo;Congress must pass legislation giving the FDA authority to regulate CBD as a dietary supplement. Time is still the enemy.&quot;&nbsp;
<h2 class="wp-block-heading">Simply Inaction&nbsp;</h2>
In 2023, the&nbsp;Coalition for Access Now,&nbsp;U.S. Pain Foundation&nbsp;and&nbsp;Balanced Veterans Network&nbsp;<a href="https://www.benzinga.com/markets/cannabis/23/12/36142004/cbds-critical-moment-coalition-pushes-for-fda-oversight" rel="noreferrer noopener" target="_blank">highlighted CBD&#39;s wide-ranging benefits</a>&nbsp;at a&nbsp;briefing hosted by a group of consumer advocates and policy experts in Washington, DC.&nbsp;
&quot;The responses to our briefings were exactly as predicted,&quot; Figi said. &quot;These bills are logical, bipartisan, unopposed, and it is long past time Congress finish what was started. CBD needs federal dietary supplement regulation so that we have clarity in labeling through third-party testing. With 4,000 CBD brands at the height of the industry and none required to test and label, even the majority of the industry agrees that something must be done quickly. The problem is and has never been opposition, the problem is simply inaction.&quot;
<img alt="" class="wp-image-248810" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/12130235/Paige-Figi-DC-Briefing-1219x1536-1-813x1024.jpg" style="height:1024px; width:813px" />
Courtesy photo ( from left to right: Dr. Rayetta Henderson - senior managing scientist in the foods &amp; consumer products practice at ToxStrategies; Kelly Fair - partner at Dentons&#39; Cannabis and Health Care practices; Paige Figi; Jen Baxter&nbsp; - ex executive director of Balanced Veteran Network; and Nicole Hemmenway - CEO of U.S. Pain Foundation).
<div>&nbsp;</div>
<div>Dr. Rayetta Henderson&nbsp;(Senior Managing Scientist in the Foods &amp; Consumer Products Practice at ToxStrategies), Kelly Fair&nbsp;(Partner at Dentons&#39; Cannabis and Health Care practices), Paige Figi (Executive Director of Coalition for Access Now), Jen Baxter&nbsp;(Executive Director of Balanced Veteran Network) and Nicole Hemmenway&nbsp;(CEO of U.S. Pain Foundation).</div>
&nbsp;
&nbsp;
<h2 class="wp-block-heading">Two Bills&nbsp;</h2>
Coalition for Access Now is supporting two bills:
1)&nbsp;<a href="https://www.congress.gov/bill/118th-congress/house-bill/1629" rel="noreferrer noopener" target="_blank">H.R. 1629</a>&nbsp;introduced in the House by Representative&nbsp;Morgan Griffith&nbsp;(R) and Representative&nbsp;Angie Craig&nbsp;(D), which would make hemp, cannabidiol derived from hemp, and any other ingredient derived from hemp lawful for use under the Federal Food, Drug, and Cosmetic Act as a dietary ingredient in a dietary supplement, and for other purposes.
2)&nbsp;<a href="https://www.congress.gov/bill/118th-congress/senate-bill/2451?s=1&amp;r=14" rel="noreferrer noopener" target="_blank">S. 2451</a>, or Hemp Access and Consumer Safety Act, sponsored by Senator&nbsp;Ron Wyden&nbsp;(D), which aims to allow for hemp-derived cannabidiol and hemp-derived cannabidiol-containing substances in dietary supplements and food.&nbsp;
Anyone who wishes to join the organization and support its efforts can learn how by visiting the non-profit&#39;s <a href="https://www.coalitionforaccess.org/">official&nbsp;website</a>.&nbsp;
&quot;While I tragically lost Charlotte in early 2020 to COVID, I celebrate her nine years living drug and hospital-free, getting to know her, out from under the fog of her seizures and medications. I still fight on for everyone in the U.S. to have her same safe access. This very worthwhile work is not finished and the responsible thing to do is to see it through to the end for the many millions of Americans that deserve better. In fact, if we don&#39;t act now to preserve access and push for federal regulation, this category is at risk, threatened from every angle,&quot; Figi concluded.&nbsp;
Featured photo: Courtesy of Brennan Linsley / AP file via <a href="https://en.wikipedia.org/wiki/Charlotte_Figi#/media/File:Charlotte_Figi_in_2014.png">Wikimedia Commons</a> and<a href="https://www.nbcnews.com/news/us-news/charlotte-figi-girl-severe-seizures-inspired-cbd-treatments-dies-13-n1179396"> NBC News</a>

Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users

Legal

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

CORRECTION: Jury Ruled In Favor Of Avadel With Respect To One Of The Contested Patents

Avadel Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware ("Court") in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ&#x2122;. &nbsp;
Avadel is pleased with the jury's decision ruling in favor of Avadel with respect to one of the contested patents. As it relates to the jury's decision against Avadel regarding the additional contested patent, the company is disappointed in the outcome. Avadel will vigorously defend its position with the pursuit of all options, including an appeal, to overturn the unfavorable aspect of the jury's decision upon final entry of the decision by the Court.
Avadel does not expect the jury's decision to impact the ongoing commercial launch or potential for LUMRYZ&#x2122; to transform the lives of people living with narcolepsy.
About LUMRYZ&#x2122;&nbsp;(sodium oxybate) for extended-release oral suspension&nbsp; LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on&nbsp;May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.     The FDA approval of LUMRYZ was supported by results from REST-ON, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial in adults with narcolepsy. LUMRYZ demonstrated statistically significant and clinically meaningful improvements in the three co-primary endpoints: EDS, clinicians' overall assessment of patients' functioning (CGI-I) and cataplexy attacks, for all three evaluated doses when compared to placebo.     With its approval, the FDA also granted seven years of Orphan Drug Exclusivity to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to currently available oxybate treatments. In particular, the FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal arousal to take a second dose.

Avadel Pharmaceuticals Issues Statement On Patent Litigation; Statement In Response To Jury Ruling In Patent Suit Brought By Jazz Pharmaceuticals Inc. Regarding LUMRYZ

RBC Capital analyst Gregory Renza reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and maintains $195 price target.

RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $195 Price Target

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $180 to $170.

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $170

In the latest quarter, 4 analysts provided ratings for Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $203.75, along with a high estimate of $235.00 and a low estimate of $160.00. A 12.37% drop is evident in the current average compared to the previous average price target of $232.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1709211643_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Jazz Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Discovering Jazz Pharmaceuticals: A Closer Look</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.35% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 15.1%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 4.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 1.31%. This signifies efficient management of assets and strong financial health.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 1.66. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst Reviews

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report). The company's ...

Truist Financial Remains a Buy on Jazz Pharmaceuticals (JAZZ)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)

Leerink Partners analyst Marc Goodman has maintained their bullish stance on JAZZ stock, giving a Buy rating yesterday. Marc Goodman has given his ...

Optimistic Outlook on Jazz Pharmaceuticals' Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immatics (IMTX – Research Report), Vor Biopharma (VO...

Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bluebird Bio (BLUE – Research Report), Sarepta The...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more… Given the growing demand for innovative medical solutions, higher R&amp;D initiatives, and rising investments in biopharma, the biotech industry is thriving. Given the backdrop, it could be wise to invest in fundamentally strong biotech stocks Incyte Corporation (<a href="https://stocknews.com/stock/INCY/">INCY</a>), Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>), and Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>) for sustained returns.
The growing foothold of personalized medicine and an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting market revenue.
As per the Grand View Research report, the global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>. Meanwhile, the U.S. biotechnology market is expected to expand at a CAGR of 12.4% from 2024 to 2030.
Moreover, last year, the global biopharma R&amp;D saw <a href="https://www.iqvia.com/newsroom/2024/02/global-biopharma-r-and-d-boasts-increased-funding">funding rise to $72 billion</a>, productivity increased with a Clinical Development Productivity Index of 17.4, and 69 novel active substances were launched worldwide. However, clinical trial starts declined by 15%, reflecting a shift toward areas like cell and gene therapies.
Further, rapid technological advancements, particularly in areas like genomics, proteomics, and bioinformatics, have led to significant breakthroughs in drug discovery, development, and manufacturing processes. Recent innovations in biotech are moving toward trends like AI, machine learning, data analytics, and automation to optimize production.
The <a href="https://www.precedenceresearch.com/artificial-intelligence-in-biopharmaceutical-market">global AI in the biopharmaceutical market</a> is projected to total about $14.07 billion by 2032, exhibiting a CAGR of 32.3%.
Given these favorable trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Incyte Corporation (<a href="https://stocknews.com/stock/INCY/">INCY</a>)
INCY is a biopharmaceutical company specializing in developing therapies for hematology /oncology, autoimmunity, and inflammation areas. The company provides JAKAFI for treating intermediate or high-risk myelofibrosis and polycythemia disease, ICLUSIG to treat chronic myeloid leukemia, and OPZELURA cream for treating atopic dermatitis.
On April 1, 2024, INCY and China Medical System Holdings Limited (CMS), through a wholly-owned dermatology medical aesthetic subsidiary of the company (CMS Skinhealth), entered a Collaboration and License Agreement for the development and commercialization of povorcitinib.
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for treating non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria. This agreement will expand the company's relationship with CMS in the Dermatology space beyond ruxolitinib cream.
On February 27, INCY announced that the FDA had accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two previous lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024.
The BLA is supported by optimistic data from the AGAVE-201 trial (NCT04710576), recently highlighted in a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.incyte.com%2Fnews-releases%2Fnews-release-details%2Fincyte-and-syndax-present-additional-data-positive-agave-201&amp;esheet=53902273&amp;newsitemid=20240227083647&amp;lan=en-US&amp;anchor=Plenary+Scientific+Session&amp;index=1&amp;md5=d6c22e83100ddabd9940d7afb40ae7ec">Plenary Scientific Session</a> at the American Society of Hematology Annual Meeting 2023.
INCY's trailing-12-month EBIT margin of 17.65% is significantly higher than the industry average of 0.89%. Further, the stock's trailing-12-month EBITDA margin of 19.98% is 276.1% higher than the industry average of 5.31%.
During the fourth quarter, which ended December 31, 2023, INCY's total revenues grew 9.3% year-over-year to $1.01 billion. The company's non-GAAP operating income rose 75.6% from the previous-year quarter to $267.70 million. Its non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> was $239.12 million, or $1.07 per share, up 71.2% and 69.8% from the prior-year quarter, respectively.
Analysts expect revenue to increase 15.2% year-over-year to $931.75 million for the fiscal first quarter that ended March 2024. Its EPS is expected to increase 134.4% year-over-year to $0.87 for the same quarter.
Shares of INCY have surged marginally intra-day to close the last trading session at $55.30.
INCY's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Value and Quality and a B in Growth. INCY is ranked #4 among 360 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/INCY/">Click here</a> to access additional INCY's ratings (Momentum, Sentiment, and Stability).
Stock #2: Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>)
Based in Dublin, Ireland, JAZZ is a biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products for unmet medical needs. It has a portfolio of products and product candidates emphasizing the areas of neuroscience, including sleep medicine and movement disorders, and in oncology, such as hematologic and solid tumors.
On April 2, 2024, JAZZ completed the rolling submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC).
If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S.
On February 7, JAZZ announced its definitive agreement with Redx Pharma to acquire global rights to the KRAS Inhibitor Program, with Redx receiving $10 million upfront and potential milestone payments of up to $870 million, expanding JAZZ's pipeline of targeted oncology therapies.
JAZZ's trailing-12-month EBIT margin of 21.14% is significantly higher than the industry average of 0.89%. Likewise, the stock's trailing-12-month EBITDA margin and levered FCF margin of 37.80% and 27.46% are significantly higher than the industry averages of 5.31% and 0.84%, respectively.
JAZZ's total revenue increased 3.3% year-over-year to $1.01 billion for the fourth quarter ended December 31, 2023. Its adjusted net income came in at $345.29 million, compared to a net loss of $4.24 million in the previous-year quarter. Also, its non-GAAP EPS came in at $5.02, compared to a loss per share of $0.07 in the prior year's quarter.
In addition, as of December 31, 2023, the company's total assets stood at $11.39 billion compared to $10.84 billion as of December 31, 2022.
Analysts predict JAZZ's revenue for the first quarter (ended March 2024) to increase 7.3% year-over-year to $957.66 million, and its EPS for the same quarter is projected to grow 6.5% year-to-year to $4.20. Moreover, the company has an excellent earnings surprise history, surpassing consensus revenue estimates in three of the trailing four quarters.
JAZZ's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
JAZZ has an A grade for Growth and Value and a B in Quality. It is ranked #2 in the same industry.
In addition to the POWR Ratings we've stated above, we also have JAZZ ratings for Momentum, Sentiment, and Stability. Get all JAZZ ratings <a href="https://stocknews.com/stock/JAZZ/">here</a>.
Stock #1: Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>)
EXEL is a biotech company specializing in oncology and dedicated to discovering, developing, and commercializing cancer treatments. The company focuses on developing inhibitors targeting cancer-related factors and collaborates with pharmaceutical companies for research and development (R&amp;D).
EXEL's trailing-12-month gross profit margin of 96.04% is 68.6% higher than the 56.95% industry average. Its 9.34% trailing-12-month EBIT margin is 781.6% higher than the 1.06% industry average. Likewise, the stock's 10.74% trailing-12-month EBITDA margin is 101.2% higher than the 5.34% industry average.
EXEL's total revenues increased 13.1% year-over-year to $479.65 million in the fourth quarter that ended December 31, 2023. The company reported a non-GAAP net income of $104.20 million, or $0.33 per share, compared to its year-ago quarter's non-GAAP net loss of $10.21 million, or $0.03 per share, respectively.
EXEL reaffirmed its fiscal year 2024 financial guidance with total revenues projected between $1.83 billion and $1.93 billion and net product revenues expected to range from $1.65 billion to $1.75 billion.
Street expects EXEL's revenue for the fiscal quarter (ended March 2024) to increase 11.5% year-over-year to $455.67 million. Its EPS is expected to grow 96.8% year-over-year to $0.24 for the same quarter.
Over the past nine months, the stock has surged 22.8% to close the last trading session at $23.72.
EXEL's POWR Ratings reflect its promising outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
The stock has an A grade for Value and a B in Growth, Sentiment, and Quality. Within the same industry, EXEL is ranked first.
<a href="https://stocknews.com/stock/EXEL/">Click here</a> to access additional ratings of EXEL for Stability and Momentum.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
INCY shares were trading at $54.60 per share on Wednesday morning, down $0.70 (-1.27%). Year-to-date, INCY has declined -13.04%, versus a 8.54% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/incy-jazz-exel-3-biotech-gems-poised-for-april-breakthroughs/>3 Biotech Gems Poised for April Breakthroughs</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Gems Poised for April Breakthroughs

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder

Jazz Pharmaceuticals: Cheap But Complicated

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price targ...

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays

BLUE

CLNN

EXEL

IMTX

INCY

LGND

NONOF

PRAX

SRPT

ZYME

Press Releases

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

Earnings

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

AGFY

CRLBF

CURLF

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)